Cited 0 times in
Attenuation of nephritis in lupus-prone mice by thalidomide
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 박용범 | - |
dc.contributor.author | 이상원 | - |
dc.contributor.author | 이수곤 | - |
dc.contributor.author | 최규헌 | - |
dc.contributor.author | 김범석 | - |
dc.contributor.author | 박규형 | - |
dc.date.accessioned | 2014-12-19T17:39:09Z | - |
dc.date.available | 2014-12-19T17:39:09Z | - |
dc.date.issued | 2012 | - |
dc.identifier.issn | 0080-2727 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/91814 | - |
dc.description.abstract | OBJECTIVES: Thalidomide has various effects, such as immune modulation, anti-angiogenicity, anti-inflammation and anti-proliferation. Moreover, thalidomide modulates the activity of NF-κB, which can up-regulate the expression of downstream genes involved in the pathophysiology of LN. Here we investigated the efficacy of thalidomide monotherapy or thalidomide plus prednisolone (PL) on nephritis in NZB/WF1 mice at different doses and compared both with a combination therapy of MMF plus PL. METHODS: Forty-three female NZB/WF1 mice were divided into eight groups (untreated; 1.7, 5 or 10 mg/kg of thalidomide alone; 1.7, 5 or 10 mg/kg of thalidomide plus 1.5 mg/kg of PL and 33.3 mg/kg of MMF plus PL). Proteinuria and histological damage were evaluated. Immune complex deposition and nuclear translocation of NF-κB in kidney tissues were assessed by immunofluorescence staining. Serum concentrations of anti-dsDNA and IgG subclasses were also measured. RESULTS: In comparison with untreated mice, mice treated with 10 mg/kg of thalidomide monotherapy showed a significant decrease in proteinuria and significantly lower glomerular and tubular damage scores, comparable to 5 or 10 mg/kg of thalidomide plus PL or MMF plus PL. Also, treatment with 10 mg/kg of thalidomide significantly decreased immune complex accumulation, reduced the serum concentration of anti-dsDNA, IgG2a and IgG2b and inhibited nuclear translocation of NF-κB in kidney tissues, comparable to standard therapy for LN. CONCLUSION: These data suggest that thalidomide might play an anti-inflammatory role in the pathophysiology of LN, and it could serve as a complementary therapy to standard induction regimens for refractory LN. | - |
dc.description.statementOfResponsibility | open | - |
dc.relation.isPartOf | RHEUMATOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Animals | - |
dc.subject.MESH | Anti-Inflammatory Agents/administration & dosage | - |
dc.subject.MESH | Anti-Inflammatory Agents/pharmacology* | - |
dc.subject.MESH | Anti-Inflammatory Agents/toxicity | - |
dc.subject.MESH | Antigen-Antibody Complex/metabolism | - |
dc.subject.MESH | DNA/metabolism | - |
dc.subject.MESH | Dose-Response Relationship, Drug | - |
dc.subject.MESH | Drug Therapy, Combination | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Glomerulonephritis/pathology | - |
dc.subject.MESH | Glomerulonephritis/prevention & control | - |
dc.subject.MESH | Immunoglobulin G/metabolism | - |
dc.subject.MESH | Immunosuppressive Agents/pharmacology | - |
dc.subject.MESH | Lupus Nephritis/blood | - |
dc.subject.MESH | Lupus Nephritis/pathology | - |
dc.subject.MESH | Lupus Nephritis/prevention & control* | - |
dc.subject.MESH | Mice | - |
dc.subject.MESH | Mice, Inbred NZB | - |
dc.subject.MESH | Mycophenolic Acid/analogs & derivatives | - |
dc.subject.MESH | Mycophenolic Acid/pharmacology | - |
dc.subject.MESH | Prednisolone/administration & dosage | - |
dc.subject.MESH | Prednisolone/pharmacology | - |
dc.subject.MESH | Proteinuria/prevention & control | - |
dc.subject.MESH | Survival Rate | - |
dc.subject.MESH | Thalidomide/administration & dosage | - |
dc.subject.MESH | Thalidomide/pharmacology* | - |
dc.subject.MESH | Thalidomide/toxicity | - |
dc.title | Attenuation of nephritis in lupus-prone mice by thalidomide | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학) | - |
dc.contributor.googleauthor | Sang-Won Lee | - |
dc.contributor.googleauthor | Yong-Beom Park | - |
dc.contributor.googleauthor | Jaeseok Yang | - |
dc.contributor.googleauthor | Kyu-Hyung Park | - |
dc.contributor.googleauthor | Soo-Kon Lee | - |
dc.contributor.googleauthor | Kyu Hun Choi | - |
dc.contributor.googleauthor | Beom Seok Kim | - |
dc.identifier.doi | 22923758 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A01579 | - |
dc.contributor.localId | A02889 | - |
dc.contributor.localId | A04043 | - |
dc.contributor.localId | A00488 | - |
dc.contributor.localId | A01441 | - |
dc.contributor.localId | A02824 | - |
dc.relation.journalcode | J02624 | - |
dc.identifier.pmid | 22923758 | - |
dc.identifier.url | http://rheumatology.oxfordjournals.org/content/51/12/2131.long | - |
dc.subject.keyword | thalidomide | - |
dc.subject.keyword | NZB/WF1 mice | - |
dc.subject.keyword | LN | - |
dc.contributor.alternativeName | Park, Yong Beom | - |
dc.contributor.alternativeName | Lee, Sang Won | - |
dc.contributor.alternativeName | Lee, Soo Kon | - |
dc.contributor.alternativeName | Choi, Kyu Hun | - |
dc.contributor.alternativeName | Kim, Beom Seok | - |
dc.contributor.alternativeName | Park, Kyu Hyung | - |
dc.contributor.affiliatedAuthor | Park, Yong Beom | - |
dc.contributor.affiliatedAuthor | Lee, Soo Kon | - |
dc.contributor.affiliatedAuthor | Choi, Kyu Hun | - |
dc.contributor.affiliatedAuthor | Kim, Beom Seok | - |
dc.contributor.affiliatedAuthor | Park, Kyu Hyung | - |
dc.contributor.affiliatedAuthor | Lee, Sang Won | - |
dc.citation.volume | 51 | - |
dc.citation.number | 12 | - |
dc.citation.startPage | 2131 | - |
dc.citation.endPage | 2140 | - |
dc.identifier.bibliographicCitation | RHEUMATOLOGY , Vol.51(12) : 2131-2140, 2012 | - |
dc.identifier.rimsid | 31214 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.